ACTU
Actuate Therapeutics, Inc. Common stockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$68.76M
P/E Ratio
—
EPS
$-1.06
Beta
—
52W High
$11.99
52W Low
$1.58
50-Day MA
$2.79
200-Day MA
$5.75
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for patients with serious diseases, particularly in the oncology sector. The company is progressing its proprietary drug candidates through comprehensive clinical trials to address significant unmet medical needs, thereby enhancing patient outcomes. With a commitment to innovative therapeutic approaches, Actuate is cultivating a strong pipeline that not only aims for strategic growth but also seeks to deliver substantial value to investors, solidifying its position in the biotechnology industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -554.00% |
| Return on Assets | -120.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.34 |
| Price-to-Book | 8.68 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $23.71M |
| Float | $8.27M |
| % Insiders | 15.50% |
| % Institutions | 57.70% |
Historical Volatility
HV 10-Day
176.16%
HV 20-Day
173.96%
HV 30-Day
151.94%
HV 60-Day
127.09%
HV Rank
99.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($13.50 target)
4
BuyData last updated: 4/29/2026